Faculty

Matthew A. Rank, M.D.

Clinical Studies

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COLCORONA) Jacksonville, Fla., Rochester, Minn. This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COLCORONA) Scottsdale/Phoenix, Ariz. This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.

A Home-Based Airway Inflammation Assay for Predicting Asthma Stability Following a Reduction in Chronic Asthma Medications Scottsdale/Phoenix, Ariz.
The purpose of this study is for patients who have decreased their chronic asthma medications to collect periodic home nasal swabs that measure levels of airway inflammation and may predict their asthma stability.
Adherence to Topical Medications for Chronic Rhinosinusitis: Medication Possession Ratio and Description of Adherence Barriers Scottsdale/Phoenix, Ariz.
The purpose of this study is to use pharmacy data to identify patient use patterns of prescribed topical medications for chronic rhinosinusitis, and then survey the patients who are not complying for the difficulties they feel prevent use.
Expanded Access to Mepolizumab for Patients with Hypereosinophilic Syndrome Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to provide a mechanism for expanded access to mepolizumab therapy for eligible patients with Hypereosinophilic Syndrome (HES).
Research Data Repository for Drug Allergy Patients: United States Drug Allergy Registry (USDAR) (USDAR) Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
This protocol outlines a prospective data collection effort from Allergy specialists at several academic and clinical institutions with the main goal of establishing and achieving a broad network and collection of allergy data consisting of clinical data and patient reported outcomes.